Zhang Hui-Ming, Zhang Bao-Ning, Xuan Li-Xue, Zhao Ping
Department of Abdominal Surgical Oncology, Cancer Hospital (Institute), Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Zhonghua Zhong Liu Za Zhi. 2009 Jun;31(6):447-51.
According to the immunohistochemical (IHC) test of ER, PR and HER-2, breast cancer can be divided into 4 different molecular subtypes: Luminal A subtype (ER or PR positive and HER-2 negative), Luminal B subtype (ER or PR positive and HER-2 positive), HER-2 subtype (ER and PR negative, HER-2 positive) and Basal-like subtype (ER, PR and HER-2 negative). This study was to analyze the clinical features of different breast cancer subtypes, and try to find the evidence of combined and individualized treatment for patients with breast cancer.
The data of 408 surgically treated breast cancer patients in the Cancer Hospital of Chinese Academy of Medical Sciences from January 1, 2002 to December 31, 2002 were collected and retrospectively analyzed. The clinicopathological features and recurrence, metastasis as well as survival of these four subtypes were compared.
Of the 408 cases, Luminal A subtype accounted for 60.8% (248/408), Luminal B subtype 7.8% (32/408), HER-2 subtype 12.5% (51/408), and Basal-like subtype 18.9% (77/408). Basal-like subtype had less lymph node metastases than other subtypes (P<0.05). HER-2 subtypes consisted of less patients aged 45 years or younger than other subtypes (P<0.05). Luminal B subtype contained less advanced cases than other subtypes (P<0.01). By August 2008, the median time of follow-up was 64 months (range, 3-79 months). Fifty-eight cases presented local recurrence or metastasis, and 51 of them died of the disease. The 5-year overall survival rates (OS) for patients with Luminal A, Luminal B, Basal-like and HER-2 subtype were 89.83%, 86.15%, 79.85% and 86.70% , respectively. The 5-year disease-free survival (DFS) rates of the four subtypes were 83.52%, 68.88%, 71.66% and 75.83%, respectively. The rate of local recurrence or metastasis in Luminal A subtype was significantly lower than that in Luminal B and Basal-like subtypes (P<0.05). The DFS time in Luminal B subtype was shorter than that in Luminal A subtype (P=0.0481). The OS and DFS time in Basal-like subtype were all shorter than that in Luminal A subtype (P=0.0077 and P=0.0306, respectively).
The distribution of each subtype in Chinese breast cancer patients is similar to that in European and American breast cancer patients. Luminal A is the most common subtype in Chinese breast cancer patients, and has a good prognosis. While Basal-like and Luminal B subtype have a poor prognosis.
根据雌激素受体(ER)、孕激素受体(PR)及人表皮生长因子受体2(HER-2)的免疫组化(IHC)检测结果,乳腺癌可分为4种不同的分子亚型:腔面A型(ER或PR阳性且HER-2阴性)、腔面B型(ER或PR阳性且HER-2阳性)、HER-2过表达型(ER和PR阴性,HER-2阳性)和基底样型(ER、PR和HER-2均阴性)。本研究旨在分析不同乳腺癌亚型的临床特征,并试图寻找乳腺癌患者联合及个体化治疗的依据。
收集中国医学科学院肿瘤医院2002年1月1日至2002年12月31日期间408例接受手术治疗的乳腺癌患者的数据,并进行回顾性分析。比较这4种亚型的临床病理特征、复发、转移及生存情况。
408例患者中,腔面A型占60.8%(248/408),腔面B型占7.8%(32/408),HER-2过表达型占12.5%(51/408),基底样型占18.9%(77/408)。基底样型的淋巴结转移少于其他亚型(P<0.05)。HER-2过表达型中45岁及以下患者少于其他亚型(P<0.05)。腔面B型的晚期病例少于其他亚型(P<0.01)。至2008年8月,中位随访时间为64个月(范围3 - 79个月)。58例出现局部复发或转移,其中51例死于该疾病。腔面A型、腔面B型、基底样型和HER-2过表达型患者的5年总生存率(OS)分别为89.83%、86.15%、79.85%和86.70%。4种亚型的5年无病生存率(DFS)分别为83.52%、68.88%、71.66%和75.83%。腔面A型的局部复发或转移率显著低于腔面B型和基底样型(P<0.05)。腔面B型的DFS时间短于腔面A型(P = 0.0481)。基底样型的OS和DFS时间均短于腔面A型(分别为P = 0.0077和P = 0.0306)。
中国乳腺癌患者各亚型的分布与欧美乳腺癌患者相似。腔面A型是中国乳腺癌患者中最常见的亚型,预后良好。而基底样型和腔面B型预后较差。